Hints and tips:
Related Special Reports
...GIC took a 25 per cent stake in CitizenM five years ago in a deal that valued the business at €2bn including debt....
...“They can go to [the] website, they can get the information they need, they can be linked to a prescriber and then a pharmacy, and do all those things independent of a primary care provider.”...
...On Thursday it also agreed a £80mn construction loan for new serviced apartment buildings, and replaced an existing construction facility with a £132mn loan on a mixed-use building that includes offices,...
...J&J is seeking a “pre-packaged” bankruptcy, allowing the company to expedite the Chapter 11 process if 75 per cent of plaintiffs back the move....
...J&J has been sitting on a significant cash pile after it decided to spin out its consumer health business Kenvue last year, with the share offering generating $13.2bn....
...Joaquin Duato, J&J’s chief executive, said the acquisition “provides a unique opportunity to accelerate our impact in cardiovascular intervention”....
...Along with striking a co-brand deal with CVS to offer Hyrimoz at a discounted price of $1,315 a month, Sandoz has a higher list price version of the biosimilar, priced similarly to Humira at more than $6,000...
...The report followed last week’s US data showing a 16 per cent decline in deal volumes in the first quarter from a year earlier....
...Eli Lilly last week announced a deal to buy a Wisconsin-based production facility for filling its injectable pens from Nexus Pharmaceuticals....
...The antitrust regulator wrote to 10 pharmaceutical manufacturers to inform them the agency had disputed their patents with the Food and Drug Administration, giving the companies a 30-day window to respond...
...Regardless of when the election is held, no ruling party has recovered from such a large polling deficit so close to an election....
...Oliver Roeder Wyoming is holy ground for hunting. Michela Tindera That’s my colleague Oliver Roeder. He’s a data journalist at the FT. Oliver Roeder There’s a lot of animals there....
...Joe Biden’s administration is planning to reclassify cannabis as a less harmful drug with a smaller legal penalty, in a historic shift for US drug policy, said people familiar with the matter....
...They are now closer to the 2016-19 monthly average of 66,000, signalling a normalisation in the market despite a steady rise in home loan costs over recent months....
...It recently launched a UK lending strategy, and has increased its overseas investments, as part of efforts to generate a higher yield from its investments....
...Pfizer is gearing up to launch its first-ever gene therapy at a list price of $3.5mn, after US regulators approved the treatment for a rare blood clotting disorder on Friday....
...“This is a difficult decision, and like others, the challenging reimbursement environment and escalating operating costs create a lack of profitability that make the care business unsustainable for us at...
...Oliver Roeder is the FT’s US senior data journalist Follow @FTMag to find out about our latest stories first and subscribe to our podcast Life and Art wherever you listen Letter in response to this article...
...I’m Rob Armstrong in New York and I’m joined today by Josh Oliver in London....
...London still has a lot going for it as a centre of natural resources investment....
...A US senate committee chaired by Bernie Sanders has launched an investigation into the steep prices charged by Novo Nordisk for its blockbuster diabetes and anti-obesity medications Ozempic and Wegovy....
...Oliver Roeder is the FT’s US senior data journalist Cartography by Steven Bernard and Sam Learner....
...McKinsey is facing a criminal investigation in the US over its work for opioid manufacturers, piling new pressure on a firm that has paid almost $1bn to settle civil claims that its advice fed an epidemic...
...“That’s what we do as a leadership team . . . is ensuring that we have back-up supply if there are any issues, regardless if it’s a regulatory issue or if it’s a natural disaster or if it’s some sort of...
...The deal, announced last month, would create a company building 22,000 homes a year with combined revenues of £7.5bn, and comes as developers weather a property market downturn....
International Edition